phosphatase-2 (SHP2) is an oncogenic phosphatase linked to various kinds of cancers. Consequently, SHP2 has emerged as a promising target for novel anti-cancer agents. Using scaffold-hopping strategy, a series of benzo[c][1,2,5]thiadiazole derivatives was designed from PTP1B inhibitors with 1H-2,3-Dihydroperimidine motif, synthesized and evaluated their biological activities against PTP1B and SHP2. Among
包含蛋白
酪氨酸磷酸酶2(SHP2)的Src同源2结构域是一种与多种癌症相关的致癌
磷酸酶。因此,SHP2已成为新型抗癌药物的有希望的靶标。运用支架跳跃策略,从具有1H -2,3-二氢
哌啶基序的
PTP1B
抑制剂中设计了一系列苯并[ c ] [1,2,5]
噻二唑衍
生物,合成并评价了它们对
PTP1B和SHP2的
生物学活性。其中,代表性化合物11g对SHP2的抑制活性为IC 50相对于SHP1和
PTP1B,SHP2的SHP2选择性为2.11±0.99μM,分别具有2.02倍和25倍的选择性,并且对
TCPTP没有可见活性。这些初步结果可能为开发具有最佳效价和改善药理特性的新型SHP2
抑制剂提供可能的机会。